The inhibition effect of Lycorine to GBM cells were solely correlated with the expression amount of EGFR, no matter wild type EGFR or EGFRvIII or other EGFR mutants, suggesting Lycorine can overcome different EGFR mutation status in treating GBM. Here, EGFR is linked to glioblastoma.